絞り込み

16645

広告

Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.

著者 Yamaguchi O , Kaira K , Mouri A , Shiono A , Hashimoto K , Miura Y , Nishihara F , Murayama Y , Kobayashi K , Kagamu H
Cancer Chemother Pharmacol.2019 Feb 13 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (84view , 0users)

Full Text Sources

Miscellaneous

Re-challenge of erlotinib after gefitinib failure is reported to yield some benefit in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation. However, little is known about the re-challenge of afatinib after 1st generate on EGFR tyrosine kinase inhibitor (TKI) failure.
PMID: 30758646 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード